A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

BACKGROUND: Venetoclax is a first-in-class targeted therapy option that is an inducer of apoptosis in chronic lymphocytic leukemia (CLL) cells. The open-label phase III CLL14 clinical trial showed that venetoclax combined with obinutuzumab (VEN+O) is superior to obinutuzumab combined with chlorambuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Anuja, van de Wetering, Gijs, Goeree, Ron, Owen, Carolyn, Desbois, Anne Marie, Barakat, Stephane, Manzoor, Beenish S., Sail, Kavita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043091/
https://www.ncbi.nlm.nih.gov/pubmed/36334238
http://dx.doi.org/10.1007/s41669-022-00375-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043091/
https://www.ncbi.nlm.nih.gov/pubmed/36334238
http://dx.doi.org/10.1007/s41669-022-00375-x

Ejemplares similares